STOCK TITAN

Electromedical Technologies Introduces the WellnessPro Infinity™

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Electromedical Technologies has completed the development of its new flagship device, the WellnessPro Infinity™, designed to relieve various pain types. The company plans to start taking pre-orders in Q1 2023, following electrical safety testing. This device boasts features like compactness, versatility in treatment modalities, and a user-friendly interface. Electromedical emphasizes the device's potential to improve patient outcomes and address the opioid crisis. The WellnessPro Infinity™ is expected to set a new standard in the bioelectronics market, with plans for ongoing updates and developments.

Positive
  • Completion of next-generation device development.
  • Versatile treatment modalities including TENS and Microcurrent.
  • User-friendly design and new Doctor-Patient Portal.
Negative
  • None.

Development of Revolutionary Next-Gen Electrotherapy Device Fully Complete

Company expects to start filling orders in Q1 2023

SCOTTSDALE, Ariz., Oct. 31, 2022 /PRNewswire/ -- InvestorsHub NewsWire -- Electromedical Technologies, Inc. (OTCQB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is very excited to introduce its new next-generation flagship device, the WellnessPro Infinity™.

See the WellnessPro Infinity™ https://electromedtech.com/wp-infinity/

"The WellnessPro Infinity™ will set an entirely new standard in the Bioelectronics marketplace"  remarked Electromedical Founder and CEO, Matthew Wolfson. "There's nothing like it on the market in terms of capability, flexibility, ease of use, and doctor-patient interface. And most important of all - Patient results. "

The NEW WellnessPro Infinity™ device features:

  • One compact device that encompasses ALL electrotherapy modalities.
  • Can produce any frequency, any wave form (typical or atypical), any level of modulation
  • Designed to support: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™,  Deep Pluse™, Cloud access and much more.
  • Unprecedented accuracy.
  • Easiest to use electrotherapy device on the market.
  • New Doctor-Patient Portal for updates and personalized treatments.

Wolfson added, " I want to thank our shareholders for the continued support, everyone at EMED and especially our incredible engineering team in Europe, for the hard work, innovation and long hours our team put in, to create a device we believe will help millions of people live happier healthier Pain Free lives and help battle the Opioid epidemic.  Now that we have completed development of our NEW flagship model by October as planned, the next step is electrical laboratory safety testing. After that, it will be production ready. Once production is underway, we will begin taking pre orders. Our goal is to start shipping units next quarter. POD development is going as planned and we look forward to sharing progress in our upcoming press releases soon. Our goal is to go to market with the WellnessPro Infinity™ first, then shortly after releasing the POD upon FDA 510k  clearance."

About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief. 

For more information, please visit www.electromedtech.com.

Note: Nonhuman preliminary studies that we are planning to start in the near future and their applications are not related to our current product in any way and are currently not cleared in the US.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Corporate Contact:
Electromedical Technologies, Inc.
Tel: 1.888.880.7888
Email: ir@electromedtech.com
https://electromedtech.com

Public Relations:
EDM Media, LLC
https://edm.media

Cision View original content:https://www.prnewswire.com/news-releases/electromedical-technologies-introduces-the-wellnesspro-infinity-301664020.html

SOURCE Electromedical Technologies, Inc.

FAQ

What is the WellnessPro Infinity™ device by EMED?

The WellnessPro Infinity™ is a bioelectronic device designed for pain relief, capable of supporting multiple electrotherapy modalities.

When will EMED start taking orders for the WellnessPro Infinity™?

Electromedical Technologies expects to start taking pre-orders in Q1 2023.

What are the features of the WellnessPro Infinity™ device?

It features compactness, flexibility in treatment modalities, unprecedented accuracy, and an easy-to-use interface.

How does EMED aim to address the opioid crisis with the WellnessPro Infinity™?

The device is intended to help relieve pain effectively, potentially reducing the reliance on opioid medication.

What is the significance of the device's completion announced on October 31, 2022?

The completion marks a critical step towards production readiness and commercialization of the WellnessPro Infinity™.

ELECTROMEDICAL TECH INC

OTC:EMED

EMED Rankings

EMED Latest News

EMED Stock Data

249.54k
612.40M
8.17%
Medical Devices
Healthcare
Link
United States of America
Scottsdale